2-(4-isopropylbenzyl)phenol | 28994-47-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-isopropylbenzyl)phenol
• 英文别名: 2-(4-Isopropyl-benzyl)-phenol；2-Hydroxy-1-(4-isopropyl-benzyl)-benzol；2-[(4-propan-2-ylphenyl)methyl]phenol
• CAS: 28994-47-0
• 化学式: C₁₆H₁₈O
• 分子量: 226.318
• InChiKey: SQQAABXPYKWMLU-UHFFFAOYSA-N

物化性质

• 沸点：
  134-137 °C(Press: 1 Torr)
• 密度：
  1.041±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(4-isopropylbenzyl)phenol 、 2-二乙氨基氯乙烷盐酸盐 在 sodium hydroxide 、 甲苯 作用下， 生成 diethyl-{2-[2-(4-isopropyl-benzyl)-phenoxy]-ethyl}-amine
  参考文献：
  名称：

  Unitary process for the production of 2-benzylphenyl beta-dimethylaminoethyl ether dihydrogen citrate

  摘要：

  公开号：

  US02768207A1
• 作为产物：
  描述：

  2-benzyloxyphenyl-4-isopropylphenylmethanol 在 盐酸 、 氢气 、 palladium(II) hydroxide 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 15.0h， 以73%的产率得到2-(4-isopropylbenzyl)phenol
  参考文献：
  名称：

  5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

  摘要：

  5a-Carba-beta-D-glucopyranose derivatives were synthesized and identified as novel SGLT2-selective inhibitors. These inhibitors exhibited potent SGLT2 inhibition with high selectivity over SGLT1. Among the tested compounds, 6f indicated the most potent hSGLT2 inhibition and the highest selectivity over hSGLT1. Moreover, the pharmacokinetics data also showed that 6h, which had the same aglycon structure as sergliflozin-active (3-active), had a threefold longer half-life time (T(1/2)) than sergliflozin (3) with a high distribution volume in db/db mice. Subsequently, 6h lowered blood glucose levels as much as 3 and showed longer hypoglycemic action than 3 in db/db mice. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.005

文献信息

• Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes
  申请人：Matsuoka Hiroharu

  公开号：US20080318874A1

  公开（公告）日：2008-12-25

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH 2 —, or —NH—; n is an integer selected between 0 and 1; R 6 and R 7 each independently is hydrogen or C 1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q 1 to Q 5 ; Ar 1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar 2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平的功能，并具有药物所需的优良特性，如持久的药物活性、代谢稳定性和安全性；以及用于预防或治疗与高血糖相关的疾病，如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：（其中A是-O-、-CH2-或-NH-；n是在0和1之间选择的整数；R6和R7各自独立地是氢或C1-6烷基；m是在1-3之间选择的整数；Q在以下式Q1至Q5之间选择；Ar1是可选的取代芳基或可选的取代杂环芳基，但杂环芳基可以与芳香环或芳香杂环结合形成融合环；Ar2是可选的取代芳基或可选的取代杂环芳基），该化合物的前药物或任一药物学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。
• Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US08048897B2

  公开（公告）日：2011-11-01

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH2—, or —NH—; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平和药物所需的良好特性，如持久的药物活性，代谢稳定性和安全性；以及用于预防或治疗由高血糖引起的疾病，如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：（其中A是—O—，—CH2—或—NH—；n是在0和1之间选定的整数；R6和R7各自独立地是氢或C1-6烷基；m是在1-3之间选定的整数；Q在以下公式Q1至Q5之间选定；Ar1是可选择取代的芳基或可选择取代的杂芳基，前提是杂芳基可以与芳香碳环或芳香杂环结合形成融合环；Ar2是可选择取代的芳基或可选择取代的杂芳基），该化合物的前药物或任一的药学上可接受的盐。还提供了一种药物，药物组合物或包含该化合物的类似物。
• NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1783110A1

  公开（公告）日：2007-05-09

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平的功能，并具有药物所需的优越性能，如持久的药物活性、代谢稳定性和安全性；以及一种药物组合物，用于预防或治疗由高血糖引起的疾病，如糖尿病，如胰岛素依赖型糖尿病（1型糖尿病）或非胰岛素依赖型糖尿病（2型糖尿病）、糖尿病并发症和肥胖症。衍生物是由式（I）代表的化合物： (其中 A 是-O-、-CH2-或-NH-；n 是选自 0 和 1 之间的整数；R6 和 R7 各自独立地是氢或 C1-6 烷基；m 是选自 1-3 之间的整数；Q 是选自下式 Q1 至 Q5 之间的整数； Ar1是任选取代的芳基或任选取代的杂芳基，条件是杂芳基可以键合到芳香族碳环或芳香族杂环上以形成融合环；以及Ar2是任选取代的芳基或任选取代的杂芳基）、该化合物的原药或二者的药学上可接受的盐。还提供了含有该化合物的药物、药物组合物或类似物。
• 10.1039/d4cy00429a
  作者：Biswas, Subir、Barman, Dipankar、Dutta, Priyanka、Gour, Nand K.、Lee, Seonghwan、Kim, Donguk、Park, Young-Bin、Bora, Tonmoy J.、Devi, Arpita、Khanam, Salma A.、Saikia, Lakshi、Karunakar, Galla V.、Zaki, Magdi E. A.、Bania, Kusum K.

  DOI：10.1039/d4cy00429a

  日期：——

  of naphthols proceeded very well at room temperature. Density functional theory (DFT) calculation on the stability of benzyl carbocation and the reaction mechanism clearly highlighted the role of the supported catalyst and its impact on the catalytic reaction. Fee radical trapping experiment supported by mass spectroscopy analysis suggested the involvement of 2-naphthyloxy radicals in selective [1,1′-binaphthalene]-2

  苯酚与伯芳香醇的苄基化以及萘酚与过氧化氢 (H 2 O 2 ) 的氧化 C-C 偶联生成联芳基衍生物长期以来一直给有机化学家带来挑战。目前的工作使用负载在沸石-NaY 基质上的钌 (Ru) 基催化剂解决了与这些反应相关的局限性。对三种不同类型的钌催化剂的详细研究提供了这样的信息：用高价钌物质产生强路易斯酸位点，在苯酚的苄基化反应中具有高产率和高邻位选择性。然而，低价Ru(0)物种的存在对催化过程产生负面影响。在 H 2 O 2存在下，2-萘酚的氧化 C-C 偶联反应快速进行，仅产生产物 BINOL。使用相同的 Ru 催化剂，苯酚的苄基化反应在 100 °C 下发生，而萘酚的 C-C 偶联在室温下进行得很好。对苄基碳正离子稳定性和反应机理的密度泛函理论（DFT）计算清楚地突出了负载型催化剂的作用及其对催化反应的影响。质谱分析支持的自由基捕获实验表明，2-萘氧基自由基参与了选择性[1,1'-联萘]-2
• EP1783110
  申请人：——

  公开号：——

  公开（公告）日：——